• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.头孢吡肟与头孢他啶治疗住院患者皮肤、手术伤口及复杂性尿路感染的随机对照研究。
Antimicrob Agents Chemother. 1991 Nov;35(11):2371-4. doi: 10.1128/AAC.35.11.2371.
2
Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections.
Am J Med. 1996 Jun 24;100(6A):76S-82S. doi: 10.1016/s0002-9343(96)00112-x.
3
Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.头孢吡肟与头孢他啶治疗严重感染的安全性和有效性
J Microbiol Immunol Infect. 2002 Sep;35(3):159-67.
4
International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.头孢吡肟与头孢他啶治疗严重细菌感染的国际比较研究。
J Antimicrob Chemother. 1993 Nov;32 Suppl B:175-86. doi: 10.1093/jac/32.suppl_b.175.
5
Low-dosage cefepime as treatment for serious bacterial infections.低剂量头孢吡肟治疗严重细菌感染
J Antimicrob Chemother. 1993 Nov;32 Suppl B:123-32. doi: 10.1093/jac/32.suppl_b.123.
6
Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.一种新型胃肠外抗生素在严重细菌感染治疗中的临床应用。
Am J Med. 1996 Jun 24;100(6A):52S-59S. doi: 10.1016/s0002-9343(96)00108-8.
7
Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment.头孢吡肟治疗中国严重细菌感染患者的疗效与安全性：与头孢他啶治疗的比较。
Int J Antimicrob Agents. 1998 Aug;10(3):245-8. doi: 10.1016/s0924-8579(98)00040-5.
8
A new therapeutic option for the treatment of pneumonia.一种治疗肺炎的新疗法选择。
Am J Med. 1996 Jun 24;100(6A):60S-67S. doi: 10.1016/s0002-9343(96)00109-x.
9
A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections.头孢吡肟与头孢他啶治疗社区获得性下呼吸道感染的对比研究。
J Antimicrob Chemother. 1993 Nov;32 Suppl B:165-73. doi: 10.1093/jac/32.suppl_b.165.
10
Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.头孢吡肟与头孢他啶治疗下呼吸道感染的比较
J Chemother. 1997 Jun;9(3):213-8. doi: 10.1179/joc.1997.9.3.213.

引用本文的文献

1
Fabrication, Characterization, and Evaluation of Bionanocomposites Based on Natural Polymers and Antibiotics for Wound Healing Applications.基于天然聚合物和抗生素的生物纳米复合材料的制备、表征及其在伤口愈合应用中的评价
Molecules. 2016 Jun 10;21(6):761. doi: 10.3390/molecules21060761.
2
Continuous beta-lactam infusion in critically ill patients: the clinical evidence.危重症患者的持续β-内酰胺输注：临床证据。
Ann Intensive Care. 2012 Aug 16;2(1):37. doi: 10.1186/2110-5820-2-37.
3
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.危重症患者中的抗生素：β-内酰胺类药物药代动力学的系统评价。
Crit Care. 2011;15(5):R206. doi: 10.1186/cc10441. Epub 2011 Sep 13.
4
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.头孢吡肟：在抗菌药物耐药性不断增加的时代的重新评估。
Expert Rev Anti Infect Ther. 2008 Dec;6(6):805-24. doi: 10.1586/14787210.6.6.805.
5
Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.头孢吡肟与哌拉西林-庆大霉素治疗发热性中性粒细胞减少癌症患者的开放性随机研究。
Antimicrob Agents Chemother. 1997 Aug;41(8):1704-8. doi: 10.1128/AAC.41.8.1704.
6
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.头孢吡肟与头孢他啶作为严重细菌感染和脓毒症综合征初始治疗的比较。
Antimicrob Agents Chemother. 1994 Mar;38(3):415-21. doi: 10.1128/AAC.38.3.415.
7
Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.头孢他啶。其抗菌活性、药代动力学特性及治疗效果的最新进展。
Drugs. 1995 Apr;49(4):577-617. doi: 10.2165/00003495-199549040-00008.
8
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢吡肟：抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.

本文引用的文献

1
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
2
In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外抗菌活性
Antimicrob Agents Chemother. 1985 Apr;27(4):574-7. doi: 10.1128/AAC.27.4.574.
3
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.BMY-28142与其他β-内酰胺类抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
4
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.卡芦莫南（RO 17-2301）、BMY-28142、氨曲南和头孢他啶对7620株连续临床分离细菌的体外活性。
Diagn Microbiol Infect Dis. 1986 Nov;5(4):345-9. doi: 10.1016/0732-8893(86)90041-6.
5
The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.新型广谱β-内酰胺酶稳定头孢菌素BMY 28142的活性。
J Antimicrob Chemother. 1986 Apr;17(4):441-52. doi: 10.1093/jac/17.4.441.
6
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.头孢匹罗（HR - 810）、WIN - 49375、BMY - 28142及其他抗生素对癌症患者医院感染重要分离菌株的体外活性
J Antimicrob Chemother. 1986 Apr;17(4):453-7. doi: 10.1093/jac/17.4.453.
7
Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.铜绿假单胞菌对头孢吡肟、头孢他啶和头孢噻肟的体外耐药频率。
Antimicrob Agents Chemother. 1988 Sep;32(9):1443-5. doi: 10.1128/AAC.32.9.1443.
8
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.头孢吡肟对头孢他啶和头孢噻肟耐药革兰阴性菌的活性及其与β-内酰胺酶水平的关系。
Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498.

头孢吡肟与头孢他啶治疗住院患者皮肤、手术伤口及复杂性尿路感染的随机对照研究。

Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.

作者信息

Gentry L O, Rodriguez-Gomez G

机构信息

St. Luke's Episcopal Hospital, Houston, Texas.

出版信息

Antimicrob Agents Chemother. 1991 Nov;35(11):2371-4. doi: 10.1128/AAC.35.11.2371.

DOI:10.1128/AAC.35.11.2371
PMID:1804010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC245387/
Abstract

We undertook a prospective, randomized open comparison of the broad-spectrum cephalosporins cefepime and ceftazidime in treatment of hospitalized subjects with skin or wound infections and complicated nosocomial urinary tract infections. Cefepime treatment (dosage, 2.0 g intravenously twice daily for 4 to 28 days) was successful in 36 (90%) of 40 infections of the skin and skin structure or wounds and in 16 (84%) of 19 nosocomial urinary tract infections. Ceftazidime treatment, 2.0 g every 8 h, was successful in 34 (96%) of 36 infections of the skin and skin structure and in 15 (88%) of 17 urinary tract infections. Microbiological eradication rates of each agent overall and for Pseudomonas aeruginosa were greater than 90%. In the cefepime group, one death occurred, contributed to by an enterococcal superinfection acquired during study drug therapy, and there were two mild and transient adverse experiences observed. Cefepime was comparable to ceftazidime in treatment of infections of the skin and skin structure requiring hospitalization and of complicated nosocomial urinary tract infections.

摘要

我们对广谱头孢菌素头孢吡肟和头孢他啶进行了一项前瞻性、随机开放比较研究，以治疗住院的皮肤或伤口感染以及复杂性医院获得性尿路感染患者。头孢吡肟治疗（剂量为静脉注射2.0 g，每日两次，共4至28天）在40例皮肤及皮肤结构或伤口感染中有36例（90%）治疗成功，在19例医院获得性尿路感染中有16例（84%）治疗成功。头孢他啶治疗剂量为每8小时2.0 g，在36例皮肤及皮肤结构感染中有34例（96%）治疗成功，在17例尿路感染中有15例（88%）治疗成功。每种药物对总体感染及铜绿假单胞菌感染的微生物清除率均大于90%。在头孢吡肟组，发生1例死亡，原因是在研究药物治疗期间获得的肠球菌二重感染，观察到2例轻度短暂不良事件。在治疗需要住院的皮肤及皮肤结构感染和复杂性医院获得性尿路感染方面，头孢吡肟与头孢他啶相当。